VRAX Stock — Virax Biolabs Group Limited Ordinary Shares

Virax Biolabs Group Limited Ordinary Shares (VRAX)

Updated October 16, 2026.

VRAX is a Stock. Total return is -100.0% over the past 4.2 years, 202.4 points behind SPY at 102.4%.

Virax Biolabs Group Limited is a United Kingdom-based biotechnology company that develops immune response detection and T cell immune profiling technologies for viral and immune-mediated diseases. The company's primary offering is ViraxImmune, a diagnostic platform for post-acute infection syndromes including long COVID and chronic fatigue syndrome, along with ImmuneSelect, a research portfolio of immune reagents and related products. The company does not currently have an established distribution schedule.

VRAX performance versus SPY

Price and return data through 2026-10-16.

Total return is -100.0% over the past 4.2 years, 202.4 points behind SPY at 102.4%. Over the past year its total return — price change plus distributions reinvested — is -90.6%. Its deepest 1-year drawdown was 91.6%.

VRAX key facts

Asset type

Stock

Asset class

Equity

Inception date

07/21/2022

Distribution frequency

None

Last close

$1.45 (as of 2026-10-16)

Market cap

$1,950,233

Average volume

40685.0

Beta

1.386

Payout ratio

0.0%

EPS

$-12.64

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

VRAX risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 91.6%.

Who may consider VRAX — and who may not

It is a weaker fit for investors who need monthly cash flow (VRAX does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on VRAX

• All tickers starting with V

Tagged: Healthcare.

Frequently asked questions